A Phase I Study on Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors
Conditions: Solid Tumor; Gynecologic Cancer; Breast Cancer; Gastrointestinal Cancer; Lung Cancer Interventions: Biological: Engineering Tumor Infiltrating Lymphocytes Sponsors: Shanghai Juncell Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors
Conditions: Solid Tumor; Gynecologic Cancer; Breast Cancer; Gastrointestinal Cancer; Lung Cancer Interventions: Biological: Engineering Tumor Infiltrating Lymphocytes Sponsors: Shanghai Juncell Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Exercise in Patients With Advanced Non-small Cell Lung Cancer
Conditions: Advanced Lung Carcinoma; First Line Treatment; Second Line Treatment; NSCLC Stage IV; NSCLC Stage IIIB; Palliative Treatment; NSCLC Stage IIIC Interventions: Behavioral: Exercise intervention Sponsors: University Hospital, Essen; German Cancer Aid Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
Conditions: SCLC, Limited Stage Interventions: Drug: Durvalumab; Drug: Chemotherapy drug of EP regimen; Radiation: radiotherapy Sponsors: Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
Conditions: Non-small Cell Lung Cancer Interventions: Drug: Trilaciclib Sponsors: Henan Cancer Hospital; Jiangsu Simcere Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Conditions: Neuroendocrine Carcinoma; Non-small Cell Lung Cancer; Histology Transformation Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Conditions: Non-Small Cell Lung Cancer; PDL1 Negative Non-Small Cell Lung Cancer (NSCLC) Interventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Drug: Nivolumab; Drug: Ipilimumab Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC
Conditions: Carcinoma; Small Cell Lung Cancer Interventions: Procedure: Drug-eluting beads bronchial arterial chemoembolization; Drug: Serplulimab; Procedure: Intravenous chemotherapy Sponsors: The Central Hospital of Lishui City Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI
Conditions: To Investigate the Potential Value of CDK4/6 Inhibitor in NSCLC Patients Undergoing Acquired Resistance to Third-generation EGFR TKIs Interventions: Drug: Osimertinib plus Dalpiciclib Sponsors: Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Conditions: Extensive Stage-small Cell Lung Cancer Interventions: Drug: Ifinatamab deruxtecan; Drug: Atezolizumab; Drug: Carboplatin; Drug: Etoposide Sponsors: Daiichi Sankyo; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab Sponsors: 7 Hills Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Conditions: NSCLC Interventions: Drug: BPI-1178; Drug: Osimertinib Sponsors: National Cancer Center, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Conditions: ALK-positive Non-small Cell Lung Cancer; Real World Study Interventions: Drug: Lorlatinib Sponsors: Sichuan Cancer Hospital and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT
Conditions: Radiation Exposure; Lung Embolism; Lung Cancer; Pneumonia Interventions: Radiation: Computed Tomography Sponsors: University of Zurich Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants
Conditions: Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation; Healthy Volunteers Interventions: Drug: BAY2927088; Drug: Midazolam Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
